Research Article Details
| Article ID: | A07379 |
| PMID: | 32520458 |
| Source: | Rev Med Suisse |
| Title: | [NASH: a less known but severe complication of diabetes]. |
| Abstract: | Nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease and is associated with type 2 diabetes in almost 60% of the cases. Its pathophysiology is complex: it consists in the accumulation of intrahepatocyte lipids and in the development of inflammation and fibrosis. Its diagnosis is based on imaging and blood tests to rule out other causes of liver damage. In doubt, the liver biopsy is the gold standard. There is currently no specific treatment available, but many molecules will soon be on the market. Therefore, it is important to actively check for NASH in type 2 diabetic patients, specially to avoid its progression to cirrhosis. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|